Lower Really Is Better for Secondary Prevention Cholesterol Targets
NEW ORLEANS -- The more intensive LDL cholesterol target guidelines recommended for secondary prevention in high-risk patients with atherosclerotic cardiovascular ...
False-Negative CAC Findings That Equal Zero Cluster in Certain Groups, Study Finds
NEW ORLEANS -- Coronary artery calcium (CAC) scoring was disproportionately less reliable as a screen for atherosclerotic plaque for people ...
High Dx Yield Supports Workup for INOCA
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found ...
Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug
DENVER -- Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of ...
PCKS9s Seen Driving Down LDL-C in Diabetes
A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with ...
Melasma: A New Era of Topical Treatment Options Galore
Combination therapies remain key as multiple agents for melasma hit the market. Medscape Medical News Source link : https://www.medscape.com/viewarticle/melasma-new-era-topical-treatment-options-galore-2026a10009j4?src=rss Author ...
Upadacitinib Significantly Improves Vitiligo vs Placebo
The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 ...
Dermatomyositis: Targeted Drug Shows Promise vs Placebo
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with ...
My Patients Are Asking for Leucovorin. Here’s What I Tell Them.
When the White House announced it was exploring leucovorin as a treatment for autism, the calls from families started pouring ...
Active Surveillance for DCIS Moves Closer to Standard Option but ‘Not Quite There’
Women who opted for active surveillance (AS) for ductal carcinoma in situ (DCIS) had ipsilateral invasive breast cancer survival (iiBCS) ...
Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy
Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy.The complement inhibitor was ...
‘Our skin is falling off and no-one can tell us why ‘
As with many skin conditions, TSW can manifest differently with different skin colours. On white skin it glows an intense ...
Fibrinolytic Beats Current Standard for Intermediate-Risk PE
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs ...
Watchman LAA Occluder Bounces Back as Alternative to OAC in CHAMPION-AF
NEW ORLEANS -- It may be reasonable for people with atrial fibrillation (Afib) to undergo percutaneous left atrial appendage (LAA) ...
Quiz Time: Can Radiologists Spot AI Deepfakes?
The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage ...
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis
NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no ...
HI-PEITHO Kicks Off ‘Golden Era’ in Pulmonary Embolism
NEW ORLEANS -- A major advance for the treatment of intermediate-risk pulmonary embolism (PE) arrived with HI-PEITHO's landmark report on ...
LAAC an Alternative for NOAC in Lower-Risk AF Patients
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the ...
Cooking and Dementia Risk; High-Dose vs Standard-Dose Flu Shot
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine ...
Roflumilast Promising for AD in Children Down to Age 3 Mos
Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to ...
